دورية أكاديمية
Radiogenomics in Interventional Oncology.
| العنوان: | Radiogenomics in Interventional Oncology. |
|---|---|
| المؤلفون: | Moussa AM; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Suite H-112, New York, NY, 10065, USA., Ziv E; Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Suite H-112, New York, NY, 10065, USA. zive@mskcc.org. |
| المصدر: | Current oncology reports [Curr Oncol Rep] 2021 Jan 02; Vol. 23 (1), pp. 9. Date of Electronic Publication: 2021 Jan 02. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : Current Science, c1999- |
| مواضيع طبية MeSH: | Neoplasms*/genetics , Neoplasms*/radiotherapy , Radiation Genomics* , Radiation Oncology*, Artificial Intelligence ; Humans |
| مستخلص: | Purpose of Review: Radiogenomics is a growing field that has garnered immense interest over the past decade, owing to its numerous applications in the field of oncology and its potential value in improving patient outcomes. Current applications have only begun to delve into the potential of radiogenomics, and particularly in interventional oncology, there is room for development and increased value of these applications. Recent Findings: The field of interventional oncology (IO) has seen valuable radiogenomic applications, from prediction of response to locoregional therapies in hepatocellular carcinoma to identification of genetic mutations in non-small cell lung cancer. Future directions that can increase the value of radiogenomics include applications that address tumor heterogeneity, predict immune responsiveness of tumors, and differentiate between oligoprogression and early widespread progression, among others. Radiogenomics, whether in terms of methodologies or applications, is still in the early stages of development and far from maturation. Future applications, particularly in the field of interventional oncology, will allow realization of its full potential. |
| فهرسة مساهمة: | Keywords: Artificial intelligence; Hepatocellular carcinoma; Interventional oncology; Non-small cell lung cancer; Radiogenomics; Radiomics |
| تواريخ الأحداث: | Date Created: 20210102 Date Completed: 20211203 Latest Revision: 20211214 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/s11912-020-00994-9 |
| PMID: | 33387095 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1534-6269 |
|---|---|
| DOI: | 10.1007/s11912-020-00994-9 |